Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, Smolen JS, Aletaha D.

Ann Rheum Dis. 2010 Jun;69(6):995-1003. doi: 10.1136/ard.2009.126714. Epub 2010 May 6. Review.

PMID:
20447950
[PubMed - indexed for MEDLINE]
2.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

PMID:
15130461
[PubMed - indexed for MEDLINE]
Free Article
3.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.

Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009.127225. Epub 2010 May 6. Review.

PMID:
20447954
[PubMed - indexed for MEDLINE]
4.

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, Landewé RB, Smolen JS, Sokka T, van der Heijde DM.

Ann Rheum Dis. 2010 Jun;69(6):987-94. doi: 10.1136/ard.2009.126748. Epub 2010 May 6. Review.

PMID:
20448280
[PubMed - indexed for MEDLINE]
5.

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA.

Drugs. 2005;65(4):473-96. Review.

PMID:
15733011
[PubMed - indexed for MEDLINE]
6.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.

Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Epub 2010 May 6. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20447957
[PubMed - indexed for MEDLINE]
7.

[Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].

Merkesdal S, Ruof J.

Z Rheumatol. 2002;61 Suppl 2:II/29-32. Review. German.

PMID:
12491120
[PubMed - indexed for MEDLINE]
8.

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

Health Technol Assess. 2004 Mar;8(11):iii, 1-91. Review.

PMID:
14982655
[PubMed - indexed for MEDLINE]
Free Article
9.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
[PubMed - indexed for MEDLINE]
10.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Epub 2014 Jan 8. Review.

PMID:
24401994
[PubMed - indexed for MEDLINE]
11.

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, Landewé R.

Ann Rheum Dis. 2010 Jun;69(6):1010-4. doi: 10.1136/ard.2009.127332. Epub 2010 May 6. Review.

PMID:
20448288
[PubMed - indexed for MEDLINE]
12.

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.

PMID:
24338344
[PubMed - indexed for MEDLINE]
13.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D.

Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20444750
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Review of health economics modelling in rheumatoid arthritis.

Emery P.

Pharmacoeconomics. 2004;22(2 Suppl 1):55-69. Review.

PMID:
15157004
[PubMed - indexed for MEDLINE]
15.

[Rheumatoid arthritis: milestones in classification and treatment].

Fiehn C.

Dtsch Med Wochenschr. 2011 Feb;136(5):203-5. doi: 10.1055/s-0031-1272510. Epub 2011 Jan 26. Review. German.

PMID:
21271482
[PubMed - indexed for MEDLINE]
16.

The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.

Tsao NW, Bansback NJ, Shojania K, Marra CA.

Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76. doi: 10.1016/j.berh.2012.07.012. Review.

PMID:
23218430
[PubMed - indexed for MEDLINE]
17.

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Nurmohamed MT, Dijkmans BA.

Drugs. 2005;65(5):661-94. Review.

PMID:
15748099
[PubMed - indexed for MEDLINE]
18.

A clinical and economic review of disease-modifying antirheumatic drugs.

Gabriel SE, Coyle D, Moreland LW.

Pharmacoeconomics. 2001;19(7):715-28. Review.

PMID:
11548909
[PubMed - indexed for MEDLINE]
19.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH.

Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. Epub 2014 Jan 7. Review.

PMID:
24399231
[PubMed - indexed for MEDLINE]
20.

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.

Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H.

Ann Rheum Dis. 2012 Mar;71(3):319-26. doi: 10.1136/ard.2011.150995. Epub 2011 Jul 28. Review.

PMID:
21803753
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk